$ACT Headlines Actavis continues pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Jan 28, 2014 at 11:56 AM

$ACT Headlines

Actavis continues pharmaceuticals dominance 11:33 a.m. Jan. 16, 2014 - The Trading Deck
13 stocks set to outperform in 2014 from Sabrient's David Brown 7:21 p.m. Jan. 14, 2014 - blogs.marketwatch.com
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
BlackBerry gains on Facebook talk; Apple red 3:00 p.m. Oct. 29, 2013 - Sue Chang
FDA recommends new limits on pain drugs 10:25 p.m. Oct. 24, 2013 - Thomas M. Burton
Large investors refuse to sell this market 11:05 a.m. Oct. 1, 2013 - The Trading Deck
A bull market not ready to be put to rest 11:14 a.m. Sept. 5, 2013 - The Trading Deck
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
James Dinan's top stock picks 9:11 a.m. Aug. 21, 2013 - Insider Monkey
Major U.S. benchmarks take technically shaky turn 11:18 a.m. Aug. 15, 2013 - Michael Ashbaugh
Dow holds major support, Nasdaq presses new highs 9:39 a.m. July 29, 2013 - Michael Ashbaugh
Perrigo to buy biotech Elan in $8.6 billion deal 3:51 a.m. July 29, 2013 - Jonathan D. Rockoff
Actavis, Warner shares climb as investors anticipate pending merger 2:07 p.m. July 26, 2013 - Russ Britt
Actavis loss widens on impairment charge 6:58 a.m. July 25, 2013 - MarketWatch.com
Charting a slow-motion rally to record territory 11:06 a.m. July 23, 2013 - Michael Ashbaugh
Charting a slow-motion rally to record territory 10:50 a.m. July 23, 2013 - Michael Ashbaugh
Hedge fund conference picks: winners and losers 6:17 p.m. July 16, 2013 - William L. Watts
Supreme Court satisfies few with ruling on generic drug settlements 4:30 p.m. June 18, 2013 - Russ Britt
Supreme Court decision on generics hits Actavis, but few other drug firms 11:46 a.m. June 17, 2013 - Russ Britt
U.S. stock benchmarks rally from obvious support 9:51 a.m. June 10, 2013 - Michael Ashbaugh

Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog 6:50 p.m. Jan. 27, 2014 - Zacks.com
Teva Falls on Negative CHMP Opinion - Analyst Blog 5:20 p.m. Jan. 27, 2014 - Zacks.com
Will Pfizer (PFE) Miss This Earnings Season? - Analyst Blog 4:50 p.m. Jan. 27, 2014 - Zacks.com
Allergan Slips on Restasis Challenge - Analyst Blog 1:50 p.m. Jan. 23, 2014 - Zacks.com
Pharma Stocks Like Actavis Continue To Dominate At The Start Of 2014 6:40 a.m. Jan. 23, 2014 - Seeking Alpha
Teva to Acquire NuPathe - Analyst Blog 4:58 p.m. Jan. 22, 2014 - Zacks.com
Narrower-than-Expected Loss at Ironwood, Shares Up - Analyst Blog 3:31 p.m. Jan. 22, 2014 - Zacks.com
Why Actavis (ACT) Has A Bright Short-Term Future? - Tale of the Tape 8:42 a.m. Jan. 22, 2014 - Zacks.com
More U.S. Companies Realize China Isn’t Worth the Trouble 4:27 a.m. Jan. 22, 2014 - InvestorPlace.com
Mallinckrodt Up on FDA Approval - Analyst Blog 12:10 p.m. Jan. 21, 2014 - Zacks.com
Will Cubist Pharma (CBST) Miss Earnings? - Analyst Blog 9:40 a.m. Jan. 21, 2014 - Zacks.com
Actavis Joins the Divestment Bandwagon - Analyst Blog 5:55 p.m. Jan. 20, 2014 - Zacks.com
Will Forest Labs (FRX) Beat Earnings Again? - Analyst Blog 11:10 a.m. Jan. 20, 2014 - Zacks.com
Actavis sells generic-pharma ops in seven European markets 2:57 a.m. Jan. 19, 2014 - Seeking Alpha
China Biotech In Review: Thermo Fisher Approved For Acquisition Of Life Technologies 2:07 a.m. Jan. 19, 2014 - Seeking Alpha
Actavis Announces Agreement with Aurobindo Pharma to Divest Commercial Operations in Seven Western European Countries 3:33 p.m. Jan. 18, 2014 - benzinga.com
Several IBD 50 Medical Companies Seen Posting Strong Q4 Profit Gains 5:16 p.m. Jan. 17, 2014 - Investors Business Daily
Actavis Leads the Way 10:21 a.m. Jan. 17, 2014 - TheStreet.com
BioLineRx Progresses with BL-8040 - Analyst Blog 5:10 p.m. Jan. 16, 2014 - Zacks.com
Actavis to exit China, Bisaro says too much trouble for too little profit 11:03 a.m. Jan. 16, 2014 - Seeking Alpha

Actavis Announces Agreement with Zhejiang Chiral Medicine Chemicals Co., Ltd to Divest Actavis Foshan, China 4:05 p.m. Jan. 24, 2014 - PR Newswire - PRF
Actavis Comments on Notification to Allergan, Inc. of Submission of Application for Restasis® 12:41 p.m. Jan. 22, 2014 - PR Newswire - PRF
Actavis Announces Agreement with Aurobindo Pharma Limited to Divest Commercial Operations in Seven Western European Countries 9:45 p.m. Jan. 17, 2014 - PR Newswire - PRF
Actavis Confirms Court Upholds Lo Loestrin® Fe Patent 5:42 p.m. Jan. 17, 2014 - PR Newswire - PRF
Pharma Industry Technical Data: Zoetis, Avanir Pharma, Actavis, and Salix Pharma 7:30 a.m. Jan. 16, 2014 - PR Newswire - PRF
Actavis Announces Preliminary Financial Performance for FY 2013 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units 7:30 a.m. Jan. 14, 2014 - PR Newswire - PRF
Upcoming Earnings Conference Calls, FDA Approvals, and Share Price Updates - Research Report on Actavis, ResMed, West Pharmaceutical, Sirona Dental Systems, and Theravance 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Actavis' Generic Version of Micardis® Receives FDA Approval 4:57 p.m. Jan. 8, 2014 - PR Newswire
Actavis to Host 2014 Investor Meeting January 31 in New York 4:25 p.m. Jan. 6, 2014 - PR Newswire
Conference Calls, Regulatory Filings, and Member Enrollment - Research Report on UnitedHealth Group, AbbVie, Lilly, Actavis, and Humana 8:00 a.m. Jan. 6, 2014 - PR Newswire
Actavis Confirms Generic NuvaRing® Patent Challenge 9:00 a.m. Dec. 24, 2013 - PR Newswire
Actavis Receives Complete Response Letter from FDA For Progestin-Only Patch 8:00 a.m. Dec. 24, 2013 - PR Newswire
Commercial Agreements, Stock Price Updates, Regulatory Approvals, Patent Litigation Settlements, and New Health Plan Strategies - Research Report on Biogen, Express Scripts, GSK, Actavis, and Aetna 8:00 a.m. Dec. 23, 2013 - PR Newswire
Actavis to Present at the 32nd Annual J.P. Morgan Healthcare Conference 9:25 a.m. Dec. 20, 2013 - PR Newswire
Vensun Pharmaceuticals, Inc. Completes Series B Financing 9:35 a.m. Dec. 19, 2013 - BusinessWire
Zimmer Holdings Names Paul Bisaro to Board of Directors 5:00 p.m. Dec. 16, 2013 - PR Newswire
Technical Research on Equities: Zoetis, Actavis, Avanir Pharma, and Salix Pharma 8:00 a.m. Dec. 16, 2013 - PR Newswire
Clinical Trial Results, Share Repurchase Transactions, Stock Price Updates, Appointments, and Investments - Research Report on AbbVie, Express Scripts, Actavis, Bristol-Myers Squibb, and GSK 8:00 a.m. Dec. 13, 2013 - PR Newswire
Actavis Announces Tentative Agreement Related to Asacol® HD Patent Challenge Litigation 8:00 a.m. Dec. 11, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Xerox Faces Probes After $130M Profit Forecast Slash

When the Trust Breaks October 29, 2026 was a gut punch for Xerox investors. Watching the outlook dive by $130 million, the coffee-feeling in the trading rooms turned into something more bitter. A $105 million boost they once celebrated from tariff receivables now seems to be a fleeting shadow, as Xerox itself scuttles its adjusted operating income for 2026 to a range of...

ATTACK SHARK's X60: A New Era in Gaming Audio

Gaming Audio Gets a Power Boost with X60 We're diving headfirst into an era where gaming headsets promise more bells and whistles than ever before. This isn't just some random gadget plopped on the market. ATTACK SHARK's X60 Gaming Headset is strutting in, guns blazing, ready to take on the heavyweights in the competitive gaming world. It's not just about being another...

DAR Logs Massive 587,000 Service Hours Nationwide

A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...

Wabi's $1.25B Valuation: A New Era for AI?

By Logan Wright Updated Oct 29, 2026 Category News Views 171

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

CopperWood Senior Living Revives Historic Campus

A Fresh Start for Peapack-Gladstone's Corporate Relic Dust off the pages of history—Peapack-Gladstone's old Pfizer/Beneficial Finance campus is getting a makeover, and boy, it’s not your run-of-the-mill renovation. We're talking adaptive reuse to the tune of nearly $200 million, morphing this architectural gem into CopperWood Senior Living. With all the office...

Pozdeutinurad Phase 3 Success Impact on Sobi and Market

Pozdeutinurad's Phase 3 Triumph Ah, the life of biotech—constant ups and downs, but when you hit a homerun, it feels like the market stands still for a second. Pozdeutinurad's recent Phase 3 REDUCE-2 study results are one of those moments for Swedish Orphan Biovitrum AB, or Sobi for short. This study showed some seriously compelling data: clinically meaningful and...

David Cornue Brings Story Insights to SXSW 2027

Crafting Stories with Precision: Cornue's Return In the world where Austin becomes a melting pot of ideas every spring, the return of David Cornue to SXSW casts a familiar, yet electrifying spark. This best-selling author and television whiz is slated to share his story magic at two workshops: one in the Lifestyle track and the other in the Film & TV track. Folks on-site...

LanguageLine AI App Earns Vizient Technology Kudos

Tech Talk: LanguageLine's AI App Gains Important Recognition Diving headfirst into the chaotic world of healthcare, LanguageLine's AI Translation App earned a standout accolade. Just announced, it's snagged the Innovative Technology Designation from Vizient, the heavyweight champ in healthcare performance improvement. On the scene since the end of October, they rolled the...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Maison Martell Bridging Artistry: Davido Meets Prince Gyasi

Maison Martell Dances to a New Beat The world's oldest cognac house, Maison Martell, is mixing things up in a way that’ll make your typical whiskey-on-the-rocks seem like child’s play. They've snagged Afrobeat heavyweight Davido and renowned visual poet Prince Gyasi to spin a fresh narrative, one where melody and imagery play in harmony. While this ain't your usual...